Biophytis S.A. is a biotechnology company developing therapeutics that slow degenerative processes and improve outcomes for patients with age-related diseases. Its lead candidate, Sarconeos (BIO101), is an orally-administered small molecule that targets neuromuscular diseases and is currently being studied in severe COVID-19 respiratory failure patients in Phase 2/3. Additionally, the company is developing Macuneos (BIO201) for the treatment of retinal diseases, and has a collaboration agreement with AFM-Telethon for the development of Sarconeos (BIO101) for treating Duchenne muscular dystrophy.